ONWARD Medical's Successful Capital Raise
ONWARD Medical N.V., a leading neurotechnology firm, has made headlines with its successful capital increase of over EUR 50 million. This funding aims to accelerate development and commercialization strategies for innovative therapies designed to restore movement and independence in individuals with spinal cord injuries.
A Strong Foundation Supported by Quality Investors
The capital raise was backed by robust demand from both existing and new high-quality, long-term institutional investors. Notable participants include Ottobock, a prominent player in prosthetics and orthotics, along with healthcare-focused investor Invus and ASR Global Impact Equity Fund. Their participation underscores the confidence in ONWARD's technology and future prospects.
Strategic Utilization of Funds
The proceeds from the capital raise are intended to extend ONWARD's cash runway into 2026, allowing the company to focus on several key initiatives:
- Enhancing development efforts for the investigational ARC-IM System that addresses critical health challenges for individuals with spinal cord injuries.
- Expanding sales and operational capacities to support the commercialization of the ARC-EX System across the U.S., Europe, and beyond.
- Scaling up quality assurance and administrative processes essential for maintaining operational excellence.
- Bolstering working capital to ensure seamless operations and corporate functions.
- Managing financial obligations, facilitating ongoing business stability.
Leadership's Perspective
"We’re thrilled to have completed this significant capital raise, supported by strong interest from quality investors," said Dave Marver, the CEO of ONWARD Medical. He highlighted the company's transition into a commercial-stage entity, marked by demand for the ARC-EX system. The raised funds will expedite the planned pivotal study for the ARC-IM system, a vital step in developing therapies that empower individuals living with spinal injuries.
Ottobock’s CEO, Oliver Jakobi, expressed a deep belief in ONWARD’s innovative approaches, noting that their investment aligns with Ottobock's future strategies in neuro-orthotics.
Market Response and Future Outlook
Trading of ONWARD's shares on the regulated markets briefly paused during the book-building phase but has since resumed, reflecting ongoing investor interest. The successful placement of 11.3 million shares at an issue price of EUR 4.50 each highlights solid market confidence. These new shares are expected to be listed on major exchanges, reinforcing ONWARD's market position and investor visibility.
About ONWARD Medical
ONWARD Medical is dedicated to developing innovative neurotechnology solutions that enhance movement, functionality, and autonomy for those with spinal cord injuries and movement disorders. With its headquarters in the Netherlands, it operates a Science and Engineering Center in Switzerland and a U.S. office in Boston. The company is publicly traded under several tickers including ONWD on Euronext and ONWRY on OTCQX.
For more details on their technologies and research initiatives, you can check ONWD.com.
Frequently Asked Questions
What is ONWARD Medical's recent achievement?
ONWARD Medical recently raised over EUR 50 million through a capital increase to support its innovative neurotechnology initiatives.
Who are the main investors in this capital raise?
Key investors include Ottobock, Invus, and ASR Global Impact Equity Fund.
How will ONWARD utilize the funds from this capital raise?
The funds will be used for development initiatives, expansion of sales operations, and enhancing quality and administrative activities.
When will the new shares be listed?
The new shares are expected to be listed on major European exchanges shortly after the capital raise.
What is the mission of ONWARD Medical?
ONWARD Medical focuses on restoring movement and independence in individuals with spinal cord injuries through innovative therapies.
